BlueCrow Capital

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, focused on developing innovative diagnostic products and services for liver cancer. Established in 2015, Ophiomics integrates bioinformatics, genomics, and artificial intelligence to enhance the diagnostic and prognostic capabilities in oncology. The company specializes in creating biomarker-based diagnostic devices that utilize molecular signatures combined with clinical parameters in predictive algorithms, facilitating early detection of hepatocellular carcinoma. With a commitment to quality, Ophiomics holds ISO 13485 and ISO 9001 certifications and boasts a diverse pipeline of products at various stages of development, from pre-clinical programs to those undergoing clinical validation.